The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Macrophage Activation in Atherosclerosis: Pathogenesis and Pharmacology of Plaque Rupture
Abstract
Atherosclerosis is still an important disease. It accounts for 39% of deaths in the U.K. and 12 million U.S citizens have atherosclerosis-associated disease. Atherosclerosis may exert clinical effects by slow narrowing, producing stable angina or dramatic rupture, producing acute coronary syndromes such as unstable angina or myocardial infarction and death. Macrophages are abundant in ruptured atherosclerotic plaques. Macrophages are innate immune effectors, i.e. they are activated without antigenic specificity. This may make them liable to indiscriminate tissue damage, since they are less selective than lymphocytes. Macrophages are recruited and activated by many signals and have an impressive armamentarium of molecules to promote tissue damage. Macrophage recruitment by abnormal endothelium over developing atherosclerotic plaques, is aided by endothelial expression of adhesion molecules (ICAM-1, VCAM, ELAM). Use of knockout mice has implicated the chemoattractant cytokine (chemokine) MCP-1 in attracting macrophage recruitment in atherosclerosis. Macrophage-activation stimuli associated with atherosclerotic risk factors include oxidised low density lipoprotein (oxLDL, "bad cholesterol"), advanced glycosylation end products (AGEs) of diabetes, angiotensin II and endothelin. Substantial work has clarified macrophage activation by OxLDL via macrophage scavenger receptors (MSRs), especially MSRA and CD36. Activated macrophages express effector molecules that kill cells and degrade extracellular matrix. These include Fas-L and nitric oxide (NO). Macrophage NO is derived from the high output inducible nitric oxide synthase (iNOS) pathway and upregulates vascular smooth muscle (VSMC) cell surface Fas, priming them for apoptosis. Activated macrophages express surface Fas-L, similar to cytotoxic T-lymphocytes and natural killer cells. Since VSMCs promote plaque stability, VSMC apoptosis may promote plaque rupture. Macrophages express multiple metalloproteinases (e.g. stromelysin) and serine proteases (e.g. urokinase) that degrade the extracellular matrix, weakening the plaque and making it rupture prone. Macrophages secrete numerous other effectors including reactive oxygen species, eicosanoids, tumour necrosis factor alpha and interleukin-1. Macrophage-derived transforming growth factor beta promotes fibrosis. Existing cardiovascular treatments including angiotensin II receptor antagonists and angiotensin converting enzyme inhibitors, aspirin, cholesterol reduction agents especially statins may inhibit macrophages. The interaction of NO-donors with macrophages and apoptosis is complex and bifunctional. Traditional anti-inflammatory agents such as glucocorticoids and cyclophosphamide have very serious side effects and are probably inappropriate. Novel anti-inflammatory agents e.g. new immunosuppressives and anti-TNF therapy may have an improved cost-benefit ratio.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inflammation in atherosclerosis
Libby, P. (2002) · Nature · doi:10.1038/nature01323 · Cited by 8,315
Alternative activation of macrophages
Gordon, S. (2003) · Nature Reviews Immunology · doi:10.1038/nri978 · Cited by 6,189
MANTOVANI, A., SOZZANI, S., LOCATI, M., ALLAVENA, P., & SICA, A. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(02)02302-5 · Cited by 5,528
Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study
Murray, C. J., & Lopez, A. D. (1997) · The Lancet · doi:10.1016/s0140-6736(96)07495-8 · Cited by 4,492
Boring, L., Gosling, J., Cleary, M., & Charo, I. F. (1998) · Nature · doi:10.1038/29788 · Cited by 1,965 · cited 1×
“MCP-1 acts via its receptor CCR-2, and correspondingly, CCR2-/- mice are also resistant to atherosclerosis [15].”
BackgroundGu, L., Okada, Y., Clinton, S. K., Gerard, C., Sukhova, G. K., Libby, P., & Rollins, B. J. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80139-2 · Cited by 1,575
Traffic Signals on Endothelium for Lymphocyte Recirculation and Leukocyte Emigration
Springer, T. A. (1995) · Annual Review of Physiology · doi:10.1146/annurev.ph.57.030195.004143 · Cited by 1,496
The oxidation hypothesis of atherosclerosis
Witztum, J. L. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92346-9 · Cited by 1,389
The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses
Schmidt, A. M., Yan, S. D., Yan, S. F., & Stern, D. M. (2001) · Journal of Clinical Investigation · doi:10.1172/jci14002 · Cited by 1,253
Matrix metalloproteinases: a tail of a frog that became a prince
Brinckerhoff, C. E., & Matrisian, L. M. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm763 · Cited by 1,105
Innate and Adaptive Immunity in the Pathogenesis of Atherosclerosis
Hansson, G. K., Libby, P., Schönbeck, U., & Yan, Z.-Q. (2002) · Circulation Research · doi:10.1161/01.res.0000029784.15893.10 · Cited by 1,024
Subendothelial retention of atherogenic lipoproteins in early atherosclerosis
Skålén, K., Gustafsson, M., Rydberg, E. K., Hultén, L. M., Wiklund, O., Innerarity, T. L., & Borén, J. (2002) · Nature · doi:10.1038/nature00804 · Cited by 1,019 · cited 1×
“It is postulated that matrix-bound sPLA2 may modify subendothelial LDL to an atherogenic form [53].”
BackgroundT lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein.
Stemme, S., Faber, B., Holm, J., Wiklund, O., Witztum, J. L., & Hansson, G. K. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.9.3893 · Cited by 943
Reduction of atherosclerosis in mice by inhibition of CD40 signalling
Mach, F., Schönbeck, U., Sukhova, G. K., Atkinson, E., & Libby, P. (1998) · Nature · doi:10.1038/28204 · Cited by 910
Protective Role of Interleukin-10 in Atherosclerosis
Mallat, Z., Besnard, S., Duriez, M., Deleuze, V., Emmanuel, F., Bureau, M. F., Soubrier, F., Esposito, B., Duez, H., Fievet, C., et al. (1999) · Circulation Research · doi:10.1161/01.res.85.8.e17 · Cited by 831
Differentiation of Monocytes into Dendritic Cells in a Model of Transendothelial Trafficking
Randolph, G. J., Beaulieu, S., Lebecque, S., Steinman, R. M., & Muller, W. A. (1998) · Science · doi:10.1126/science.282.5388.480 · Cited by 809
Shah, P. K., Falk, E., Badimón, J. J., Fernández‐Ortíz, A., Mailhac, A. C., Villareal-Levy, G., Fallon, J. T., Regnström, J., & Fuster, V. (1995) · PubMed · Cited by 722
The biology of the receptor for advanced glycation end products and its ligands
Schmidt, A. M., Yan, S. D., Yan, S. F., & Stern, D. M. (2000) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/s0167-4889(00)00087-2 · Cited by 691
Structure, Function, and Inhibition of Chemokines
Fernandez, E. J., & Lolis, E. (2002) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.42.091901.115838 · Cited by 609
CD40 Signaling and Plaque Instability
Schönbeck, U., & Libby, P. (2001) · Circulation Research · doi:10.1161/hh2401.101272 · Cited by 566
Kannel, W. B., Neaton, J. D., Wentworth, D., Thomas, H. E., Stamler, J., Hulley, S. B., & Kjelsberg, M. O. (1986) · American Heart Journal · doi:10.1016/0002-8703(86)90481-3 · Cited by 501
Collins, R. G., Velji, R., Guevara, N. V., Hicks, M. J., Chan, L., & Beaudet, A. L. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.1.189 · Cited by 493
Forrester, K., Ambs, S., Lupold, S. E., Kapust, R. B., Spillare, E. A., Weinberg, W. C., Felley-Bosco, E., Wang, X. W., Geller, D. A., Tzeng, E., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.6.2442 · Cited by 469
Nitric Oxide as a Bifunctional Regulator of Apoptosis
Kim, Y.-M., Bombeck, C. A., & Billiar, T. R. (1999) · Circulation Research · doi:10.1161/01.res.84.3.253 · Cited by 464
Plasmin and Matrix Metalloproteinases in Vascular Remodeling
Lijnen, H. R. (2001) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1616230 · Cited by 453
Buttery, L. D. K., Springall, D. R., Chester, A. H., Evans, T. J., Standfield, E. N., Parums, D. V., Yacoub, M. H., & Polak, J. M. (1996) · PubMed · Cited by 405
Ridker, P. M., Rifai, N., Rose, L., Buring, J. E., & Cook, N. R. (2003) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000058687.18516.14 · Cited by 390
Kislinger, T., Tanji, N., Wendt, T., Qu, W., Lu, Y., Ferran, L. J., Taguchi, A., Olson, K., Bucciarelli, L., Goova, M., et al. (2001) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.21.6.905 · Cited by 285
Ohgami, N., Nagai, R., Ikemoto, M., Arai, H., Kuniyasu, A., Horiuchi, S., & Nakayama, H. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m006545200 · Cited by 244
Lijnen, H. R., Van Hoef, B., Lupu, F., Moons, L., Carmeliet, P., & Collen, D. (1998) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.18.7.1035 · Cited by 221
Dansky, H. M., Barlow, C. B., Lominska, C., Sikes, J. L., Kao, C., Weinsaft, J., Cybulsky, M. I., & Smith, J. D. (2001) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/hq1001.096625 · Cited by 219
Human Monocytes/Macrophages Release TNF-α in Response to Ox-LDL
Jovinge, S., Ares, M. P. S., Kallin, B., & Nilsson, J. (1996) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.16.12.1573 · Cited by 216
Boyle, J. J., Bowyer, D. E., Weissberg, P. L., & Bennett, M. R. (2001) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/hq0901.094279 · Cited by 155
Self-citationASSOCIATION OF CORONARY PLAQUE RUPTURE AND ATHEROSCLEROTIC INFLAMMATION
Boyle, J. J. (1997) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199701)181:1<93::aid-path696>3.0.co;2-h · Cited by 150
Self-citationRezaie-Majd, A., Prager, G. W., Bucek, R. A., Schernthaner, G.-H., Maca, T., Kress, H. G., Valent, P., Binder, B. R., Minar, E., & Baghestanian, M. (2003) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000059384.34874.f0 · Cited by 146
Jormsjö, S., Wuttge, D. M., Sirsjö, A., Whatling, C. A., Hamsten, A., Stemme, S., & Eriksson, P. O. (2002) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64254-x · Cited by 136
Angiotensin II type 1 receptor-mediated peroxide production in human macrophages
Yanagitani, Y., Rakugi, H., Okamura, A., Moriguchi, K., Takiuchi, S., Ohishi, M., Suzuki, K., Higaki, J., & Ogihara, T. (1999) · Hypertension · doi:10.1161/01.hyp.33.1.335 · Cited by 118
Keidar, S., Heinrich, R., Kaplan, M., Hayek, T., & Aviram, M. (2001) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/hq0901.095547 · Cited by 118
Boyle, J. J., Weissberg, P. L., & Bennett, M. R. (2002) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000033517.48444.1a · Cited by 115
Self-citationSakamoto, H., Aikawa, M., Hill, C. C., Weiss, D., Taylor, W. R., Libby, P., & Lee, R. T. (2001) · Circulation · doi:10.1161/hc2701.091070 · Cited by 105
Biomechanical Regulation of Human Monocyte/Macrophage Molecular Function
Yang, J.-H., Sakamoto, H., Xu, E. C., & Lee, R. T. (2000) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65051-1 · Cited by 84
Babaei, S. (2000) · Cardiovascular Research · doi:10.1016/s0008-6363(00)00169-3 · Cited by 79
Guo, J., Eck, M. V., Twisk, J., Maeda, N., Benson, G. M., Groot, P. H. E., & van Berkel, T. J. C. (2003) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000058431.78833.f5 · Cited by 72
The Effect of Endothelin-1 on Nuclear Factor Kappa B in Macrophages
Wilson, S. H., Simari, R. D., & Lerman, A. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.5485 · Cited by 56
Ribardo, D. A., Crowe, S. E., Kuhl, K. R., Peterson, J. W., & Chopra, A. K. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m006690200 · Cited by 54
Clinical overview of leukocyte adhesion and migration: where are we now?
Marshall, D., & Haskard, D. O. (2002) · Seminars in Immunology · doi:10.1006/smim.2001.0350 · Cited by 53
Menshikov, M. Y., Elizarova, E., Plakida, K., Timofeeva, A. V., Khaspekov, G. L., Beabealashvilli, R. S., Bobik, A., & Va, T. (2002) · Biochemical Journal · doi:10.1042/bj20020663 · Cited by 53
Soilleux, E. J., Morris, L., Trowsdale, J., Coleman, N., & Boyle, J. (2002) · The Journal of Pathology · doi:10.1002/path.1205 · Cited by 52
Self-citationSpatial Hemodynamics, the Endothelium, and Focal Atherogenesis: A Cell Cycle Link?
Davies, P. F. (2000) · Circulation Research · doi:10.1161/01.res.86.2.114 · Cited by 51
Newby, A. C., Libby, P., & van der Wal, A. C. (1999) · Cardiovascular Research · doi:10.1016/s0008-6363(98)00329-0 · Cited by 51
Hernández, M., Fuentes, L., Avilés, F. J. F., Crespo, M. S., & Nieto, M. L. (2002) · Circulation Research · doi:10.1161/hh0102.102978 · Cited by 49
Signalling heterogeneity as a contributing factor in macrophage functional diversity
Riches, D. W. H. (1995) · Seminars in Cell Biology · doi:10.1016/s1043-4682(05)80008-x · Cited by 31
Cholesterol and public policy.
Larosa, J. (1994) · Atherosclerosis · doi:10.1016/0021-9150(94)90159-7 · Cited by 7
Cited by
Regulation of inflammation by short chain fatty acids
Vinolo, M. A. R., Rodrigues, H. G., Nachbar, R. T., & Curi, R. (2011) · Nutrients · doi:10.3390/nu3100858 · Cited by 1,724
Endothelial Cell Metabolism in Normal and Diseased Vasculature
Eelen, G., de Zeeuw, P., Simons, M., & Carmeliet, P. (2015) · Circulation Research · doi:10.1161/circresaha.116.302855 · Cited by 627
Folate Receptor-Mediated Drug Targeting: From Therapeutics to Diagnostics
Hilgenbrink, A. R., & Low, P. S. (2005) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20457 · Cited by 625
New Approaches to Sepsis: Molecular Diagnostics and Biomarkers
Reinhart, K., Bauer, M., Riedemann, N. C., & Hartog, C. S. (2012) · Clinical Microbiology Reviews · doi:10.1128/cmr.00016-12 · Cited by 533
Monocyte recruitment and foam cell formation in atherosclerosis
Bobryshev, Y. V. (2006) · Micron · doi:10.1016/j.micron.2005.10.007 · Cited by 374
Metadata
- Authors
- Boyle, J.
- Venue
- Current Vascular Pharmacology
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2005-01-01
- Volume
- 3
- Issue
- 1
- Pages
- 63-68
- ISSN
- 1570-1611 (ISSN-L)
- OpenAlex
- W2091557419
- Cited by
- 293
- References
- 53
- FWCI
- 6.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.